Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Rhea-AI Summary

On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.

Positive

• Appointment of Patrick Gallagher expected to enhance strategic initiatives and partnerships.
• Gallagher's extensive experience in biotech and pharmaceuticals may drive value creation.

Negative

• Potential continuity concerns as a new executive joins during a pivotal time.

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer.

“Patrick is an accomplished biotech executive who brings significant strategic and transactional expertise to Sensei. He has worked across the biotechnology, Big Pharma, venture and banking sectors and has a track record of tailoring partnerships and transactions to build value,” said John Celebi, president and chief executive officer of Sensei Biotherapeutics. “We’re thrilled to add him to our leadership team at a pivotal moment as we work to optimize both of our platforms and advance key programs towards important milestones.”

Mr. Gallagher has nearly 20 years’ experience in pharmaceuticals and biotech, having played a material role in transactions and value creation for public and private companies, including numerous Flagship Pioneering portfolio companies, Nuvation Bio, Walking Fish Therapeutics, Radius Health, AbbVie and multiple investment banking clients. Mr. Gallagher joins Sensei from Binney Street Partners, where he served as managing director supporting repeat entrepreneurs and venture funds to build, partner and transact biotech companies. Prior to this, he held multiple roles of increasing responsibility across investment banking, buy-side transactions, sell-side transactions, venture creation, and has both strategy and operational experience contributing to value creation from novel science. Mr. Gallagher earned a B.A. in psychology from Ohio Wesleyan University, and both an MBA and MPH from Boston University.

“Sensei is built on a commitment to truly innovative science combined with a focus on smart and nimble execution that is so critical in today’s challenging environment,” said Mr. Gallagher. “I’m excited to join the team and look forward to applying my experience in corporate development to help Sensei advance our shared mission to work with the immune system to combat cancer.”

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company that focuses on overturning the body’s tolerance of cancer cells and directing its defenses against them. Sensei has developed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Erin Colgan
Chief Financial Officer
Sensei Biotherapeutics
ecolgan@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What is the significance of Patrick Gallagher's appointment as Chief Business Officer at SNSE?

Gallagher's appointment is significant as he brings nearly 20 years of experience in biotech and pharmaceuticals, which is anticipated to enhance Sensei's strategic initiatives and partnerships.

What experience does Patrick Gallagher have related to SNSE?

Gallagher has a strong background with various biotech and pharmaceutical companies, including roles in investment banking and corporate development, which positions him well to drive value creation at Sensei.

How might Gallagher's leadership impact Sensei Biotherapeutics?

Gallagher's leadership could positively impact Sensei by optimizing their platforms and advancing key programs, particularly as the company navigates critical milestones.

What challenges might SNSE face with the new leadership change?

Sensei may face continuity challenges as Gallagher steps into the role during a pivotal time for the company, potentially creating a period of adjustment.